ITI Pharma and Healthcare Fund vs WhiteOak Capital Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
ITI Pharma and Healthcare Fund is a Thematic fund and WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund. In the year to 30-10-2026, ITI Pharma and Healthcare Fund (Direct) returned 9.4% and WhiteOak Capital Pharma and Healthcare Fund (Direct) returned 19.5%. ITI Pharma and Healthcare Fund charges 0.89% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07% (Direct plans). Their portfolios overlap 53.6%: they hold 22 of the same securities.
ITI Pharma and Healthcare Fund
Thematic
- 1 year return
- 9.4%
- Expense ratio
- 0.89%
- NAV
- ₹19.46
WhiteOak Capital Pharma and Healthcare Fund
Sectoral
- 1 year return
- 19.5%
- Expense ratio
- 1.07%
- NAV
- ₹17.44
Which is better, ITI Pharma and Healthcare or WhiteOak Capital Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- WhiteOak Capital Pharma and Healthcare returned more over 1 year: 19.5% against 9.4%.
- ITI Pharma and Healthcare costs less: 0.89% a year against 1.07% (Direct plans).
- WhiteOak Capital Pharma and Healthcare fell less in its worst fall since 07-02-2024: −15.4% against −17.1%.
- WhiteOak Capital Pharma and Healthcare is the larger fund: ₹927 Cr against ₹266 Cr.
- Their portfolios overlap 53.6%: 22 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | ITI Pharma and Healthcare Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Fund house | ITI Mutual Fund | WhiteOak Capital Mutual Fund |
| Category | Thematic | Sectoral |
| AUM | ₹266 Cr (30-09-2026) | ₹927 Cr (30-09-2026) |
| NAV | ₹19.46 (Direct) | ₹17.44 (Direct) |
| Expense ratio (Direct) | 0.89% | 1.07% |
| Expense ratio (Regular) | 2.59% | 2.75% |
| Riskometer | Very High | Very High |
| Benchmark | NIFTY Healthcare TRI | BSE Healthcare TRI |
| Launch date | 08-11-2021 | 06-02-2024 |
| Minimum investment | ₹5,000 | ₹500 |
| Lock in | None | None |
| Fund managers | Animesh Singh, Nilay Dalal | Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal |
| Exit load | Exit load of 0.50%, if redeemed within 3 months. | Nil |
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 0.00% | −1.04% | +11.74% | +9.43% | +20.30% | -- | -- |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | +0.92% | +1.33% | +17.99% | +19.53% | -- | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | -- | -- | -- |
Category average: the average of the 235 Thematic funds and the 20 Sectoral funds, same plan type.
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Year-wise Returns
| Year | ITIITI Pharma and Healthcare | WhiteOak CapitalWhiteOak Capital Pharma and Healthcare |
|---|---|---|
| 2026to date | +14.07% | +22.83% |
| 2025 | −8.24% | +1.84% |
| 2024 | +43.95% | -- |
| 2023 | +34.39% | -- |
| 2022 | −6.68% | -- |
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against Nifty Healthcare Index TRI, the benchmark of ITI Pharma and Healthcare Fund
Rolling returns
Every 1-year holding period, 424 of them, one for each trading day from 07-02-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
ITI Pharma and Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
Nifty Healthcare Index TRI
to
Mar 2025Jul 2024
to
Jul 2025Oct 2024
to
Oct 2025Feb 2025
to
Feb 2026May 2025
to
May 2026Sept 2025
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare | 27.4 | 14.9 | 19.8 | 15.6 | 16.0 | 6.1 | 0.2 | 6.9% | 6.6% | −9.3% | 25.4% | 30% |
| WhiteOak Capital Pharma and Healthcare | 0.0 | 6.6 | 14.9 | 16.3 | 18.6 | 19.3 | 24.3 | 18.0% | 18.4% | 0.6% | 35.5% | 100% |
| Nifty Healthcare Index TRI | 5.0 | 23.1 | 20.8 | 31.1 | 19.1 | 0.9 | 0.0 | 9.4% | 10.5% | −4.4% | 22.0% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty Healthcare Index TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 07-02-2024. Past returns do not promise future returns.
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-02-2024 to 30-10-2026: 33 instalments, ₹3,30,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct) | ₹3,30,000 | ₹3,81,641 | ₹51,641 | 10.6% |
| WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct) | ₹3,30,000 | ₹4,37,625 | ₹1,07,625 | 21.2% |
ITI Pharma and HealthcareITI Pharma and Healthcare Fund (Direct)
WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | ITI Pharma and Healthcare Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.43% | +19.53% |
| Standard deviation | 13.63% | 13.75% |
| Sharpe ratio | 0.31 | 1.04 |
| Sortino ratio | 0.44 | 1.57 |
| Maximum drawdown | −11.7% (29-01-2026) | −9.8% (23-10-2026) |
| Beta | 0.91 | 0.97 |
| Alpha | −1.48% | +7.36% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | ITI Pharma and Healthcare Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +14.34% | +22.30% |
| Standard deviation | 13.44% | 14.35% |
| Sharpe ratio | 0.63 | 1.14 |
| Sortino ratio | 0.89 | 1.62 |
| Maximum drawdown | −17.7% (17-06-2022) | −15.4% (28-02-2025) |
| Beta | 0.84 | 0.97 |
| Alpha | +1.08% | +7.59% |
From daily NAVs, 11-11-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
ITI Pharma and Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
Nifty Healthcare Index TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | −17.1% | 02-01-2025 | 03-03-2025 | 24-06-2026 | 16 months | −4.2% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | −15.4% | 02-01-2025 | 28-02-2025 | 14-07-2025 | 4 months | −3.0% |
| Nifty Healthcare Index TRI | −15.7% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −2.9% |
From daily values since 07-02-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
ITI Pharma and Healthcare Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
Nifty Healthcare Index TRI
Against Nifty Healthcare Index TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| ITI Pharma and Healthcare Fund (Direct) | 92% | 89% | 5.36% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | 107% | 67% | 5.62% |
From month-end values since 07-02-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: ITI Pharma and Healthcare Fund, September 2026; WhiteOak Capital Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 53.6%
- Held by both
- 22
- Only in ITI Pharma and Healthcare
- 15
- Only in WhiteOak Capital Pharma and Healthcare
- 37
| Security | % of ITI Pharma and Healthcare | % of WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Divi's Laboratories Limited | 9.51% | 8.36% |
| Sun Pharmaceutical Industries Limited | 11.96% | 7.11% |
| Torrent Pharmaceuticals Limited | 4.78% | 6.26% |
| Laurus Labs Limited | 4.02% | 3.91% |
| Apollo Hospitals Enterprise Limited | 5.45% | 3.75% |
| Cipla Limited | 4.19% | 3.68% |
| Neuland Laboratories Limited | 3.07% | 2.60% |
| Aurobindo Pharma Limited | 4.01% | 2.09% |
| IPCA Laboratories Limited | 1.94% | 2.88% |
| Sai Life Sciences Limited | 1.87% | 3.28% |
| Max Healthcare Institute Limited | 4.49% | 1.84% |
| Global Health Limited | 2.85% | 1.82% |
| Fortis Healthcare Limited | 2.77% | 1.36% |
| Anthem Biosciences Limited | 1.25% | 1.57% |
| Shaily Engineering Plastics Limited | 1.22% | 1.84% |
| Mankind Pharma Limited | 3.78% | 1.20% |
| Piramal Pharma Limited | 1.27% | 1.06% |
| Rainbow Childrens Medicare Limited | 1.00% | 1.15% |
| Gland Pharma Limited | 1.03% | 0.93% |
| Zydus Lifesciences Limited | 0.73% | 2.81% |
| Supriya Lifescience Limited | 1.00% | 0.69% |
| Biocon Limited | 0.81% | 0.42% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 53.6% means 53.6% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in ITI Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Dr. Reddy's Laboratories Limited | 4.78% |
| Cohance Lifesciences Limited | 3.14% |
| Alkem Laboratories Limited | 3.09% |
| Abbott India Limited | 2.14% |
| Lupin Limited | 2.04% |
Largest holdings only in WhiteOak Capital Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Dr. Lal Path Labs Limited | 2.35% |
| Corona Remedies Limited | 2.34% |
| Thyrocare Technologies Limited | 2.27% |
| Ajanta Pharma Limited | 2.01% |
| Krishna Institute Of Medical Sciences Limited | 1.85% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | ITI Pharma and Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Equity | 99.3% | 90.7% |
| Debt | 0.0% | 3.1% |
| Cash and others | 0.7% | 6.1% |
Market cap of stocks
| Market cap | ITI Pharma and Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Large Cap | 35.9% | 29.2% |
| Mid Cap | 40.5% | 21.7% |
| Small Cap | 23.0% | 37.5% |
| Not on AMFI's list | 0.0% | 2.4% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | ITI Pharma and Healthcare | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.8% | 61.2% |
| Healthcare Services | 20.9% | 23.0% |
| Chemicals & Petrochemicals | 0.9% | 3.3% |
| Consumer Durables | 1.2% | 1.8% |
| Healthcare Equipment & Supplies | 1.5% | 1.4% |
The six largest sectors of each fund's stocks, % of the fund.
ITI Pharma and Healthcare vs WhiteOak Capital Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | ITI Pharma and Healthcare Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.89% | 1.07% |
| Base expense ratio (Direct) | 0.58% | 0.54% |
| Total expense ratio (Regular) | 2.59% | 2.75% |
| Base expense ratio (Regular) | 2.10% | 1.96% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare ITI Pharma and Healthcare with
Compare WhiteOak Capital Pharma and Healthcare with
- WhiteOak Capital Pharma and Healthcare vs DSP Healthcare
- WhiteOak Capital Pharma and Healthcare vs Nippon India Pharma
- WhiteOak Capital Pharma and Healthcare vs Bandhan Transportation and Logistics
- WhiteOak Capital Pharma and Healthcare vs Nippon India Power & Infra
- WhiteOak Capital Pharma and Healthcare vs Invesco India Financial Services
ITI Pharma and Healthcare Fund vs WhiteOak Capital Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between ITI Pharma and Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is a Thematic fund, WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund, run by ITI Mutual Fund and WhiteOak Capital Mutual Fund. Their portfolios overlap 53.6%. ITI Pharma and Healthcare Fund charges 0.89% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07%.
Which has given higher returns, ITI Pharma and Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
Over 1 year: ITI Pharma and Healthcare Fund +9.43%, WhiteOak Capital Pharma and Healthcare Fund +19.53%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, ITI Pharma and Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund charges less: 0.89% a year against 1.07%. These are the Direct plans' total expense ratios reported to AMFI.
How much do ITI Pharma and Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund overlap?
53.6%. They hold 22 of the same securities, the largest shared ones being DIVISLAB, SUNPHARMA, TORNTPHARM. From each fund's latest monthly portfolio.
Which is riskier, ITI Pharma and Healthcare Fund or WhiteOak Capital Pharma and Healthcare Fund?
On SEBI's riskometer, ITI Pharma and Healthcare Fund is rated Very High and WhiteOak Capital Pharma and Healthcare Fund Very High. Over 1 years, the standard deviation of daily returns was 13.63% and 13.75% a year.
Can I invest in both ITI Pharma and Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
Yes. 53.6% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages ITI Pharma and Healthcare Fund and WhiteOak Capital Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund: Animesh Singh, Nilay Dalal. WhiteOak Capital Pharma and Healthcare Fund: Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.